SCYNEXIS INC (SCYX) Fundamental Analysis & Valuation

NASDAQ:SCYX • US8112922005

Current stock price

0.8129 USD
-0.02 (-2.94%)
At close:
0.83 USD
+0.02 (+2.1%)
Pre-Market:

This SCYX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. SCYX Profitability Analysis

1.1 Basic Checks

  • In the past year SCYX has reported negative net income.
  • SCYX had a negative operating cash flow in the past year.
  • SCYX had negative earnings in 4 of the past 5 years.
  • SCYX had negative operating cash flow in 4 of the past 5 years.
SCYX Yearly Net Income VS EBIT VS OCF VS FCFSCYX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -14.58%, SCYX is in the better half of the industry, outperforming 64.06% of the companies in the same industry.
  • The Return On Equity of SCYX (-17.44%) is better than 70.83% of its industry peers.
Industry RankSector Rank
ROA -14.58%
ROE -17.44%
ROIC N/A
ROA(3y)4.71%
ROA(5y)-16.97%
ROE(3y)11.93%
ROE(5y)-401.32%
ROIC(3y)N/A
ROIC(5y)N/A
SCYX Yearly ROA, ROE, ROICSCYX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K

1.3 Margins

  • SCYX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SCYX Yearly Profit, Operating, Gross MarginsSCYX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10K -20K -30K -40K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. SCYX Health Analysis

2.1 Basic Checks

  • SCYX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • SCYX has more shares outstanding than it did 1 year ago.
  • SCYX has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for SCYX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SCYX Yearly Shares OutstandingSCYX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
SCYX Yearly Total Debt VS Total AssetsSCYX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • SCYX has an Altman-Z score of -6.72. This is a bad value and indicates that SCYX is not financially healthy and even has some risk of bankruptcy.
  • SCYX's Altman-Z score of -6.72 is on the low side compared to the rest of the industry. SCYX is outperformed by 66.15% of its industry peers.
  • SCYX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.72
ROIC/WACCN/A
WACC9.23%
SCYX Yearly LT Debt VS Equity VS FCFSCYX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M

2.3 Liquidity

  • A Current Ratio of 7.04 indicates that SCYX has no problem at all paying its short term obligations.
  • SCYX has a Current ratio of 7.04. This is in the better half of the industry: SCYX outperforms 75.52% of its industry peers.
  • SCYX has a Quick Ratio of 7.04. This indicates that SCYX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 7.04, SCYX is in the better half of the industry, outperforming 75.52% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.04
Quick Ratio 7.04
SCYX Yearly Current Assets VS Current LiabilitesSCYX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. SCYX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 59.56% over the past year.
  • SCYX shows a strong growth in Revenue. In the last year, the Revenue has grown by 449.95%.
  • The Revenue has been growing by 59.36% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)59.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%368.94%
Revenue 1Y (TTM)449.95%
Revenue growth 3Y59.36%
Revenue growth 5YN/A
Sales Q2Q%1808.5%

3.2 Future

  • SCYX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.98% yearly.
  • Based on estimates for the next years, SCYX will show a very strong growth in Revenue. The Revenue will grow by 31.87% on average per year.
EPS Next Y67.52%
EPS Next 2Y-58.21%
EPS Next 3Y-18.91%
EPS Next 5Y16.98%
Revenue Next Year660.43%
Revenue Next 2Y-38.5%
Revenue Next 3Y21.54%
Revenue Next 5Y31.87%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
SCYX Yearly Revenue VS EstimatesSCYX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M
SCYX Yearly EPS VS EstimatesSCYX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -5 -10 -15 -20 -25

More info and screens

Find the best growth stocksShow best growing peers

0

4. SCYX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SCYX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SCYX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SCYX Price Earnings VS Forward Price EarningsSCYX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SCYX Per share dataSCYX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

  • A cheap valuation may be justified as SCYX's earnings are expected to decrease with -18.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-58.21%
EPS Next 3Y-18.91%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SCYX Dividend Analysis

5.1 Amount

  • No dividends for SCYX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SCYX Fundamentals: All Metrics, Ratios and Statistics

SCYNEXIS INC

NASDAQ:SCYX (3/27/2026, 8:00:01 PM)

Premarket: 0.83 +0.02 (+2.1%)

0.8129

-0.02 (-2.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-04
Earnings (Next)05-13
Inst Owners21.26%
Inst Owner Change-23.3%
Ins Owners3.71%
Ins Owner Change21.33%
Market Cap36.30M
Revenue(TTM)20.60M
Net Income(TTM)-8.61M
Analysts84.44
Price Target3.54 (335.48%)
Short Float %2.99%
Short Ratio2.88
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)52%
Min EPS beat(2)16.67%
Max EPS beat(2)87.34%
EPS beat(4)4
Avg EPS beat(4)42.54%
Min EPS beat(4)16.67%
Max EPS beat(4)87.34%
EPS beat(8)7
Avg EPS beat(8)38.74%
EPS beat(12)9
Avg EPS beat(12)16.44%
EPS beat(16)12
Avg EPS beat(16)19.93%
Revenue beat(2)2
Avg Revenue beat(2)123.71%
Min Revenue beat(2)121.75%
Max Revenue beat(2)125.68%
Revenue beat(4)4
Avg Revenue beat(4)259.6%
Min Revenue beat(4)22.61%
Max Revenue beat(4)768.35%
Revenue beat(8)6
Avg Revenue beat(8)170.95%
Revenue beat(12)9
Avg Revenue beat(12)138.84%
Revenue beat(16)10
Avg Revenue beat(16)99.2%
PT rev (1m)-5.27%
PT rev (3m)-5.27%
EPS NQ rev (1m)14.29%
EPS NQ rev (3m)7.69%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)96.81%
Revenue NY rev (3m)96.81%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.76
P/FCF N/A
P/OCF N/A
P/B 0.74
P/tB 0.74
EV/EBITDA N/A
EPS(TTM)-0.18
EYN/A
EPS(NY)-0.06
Fwd EYN/A
FCF(TTM)-0.12
FCFYN/A
OCF(TTM)-0.12
OCFYN/A
SpS0.46
BVpS1.11
TBVpS1.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -14.58%
ROE -17.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)4.71%
ROA(5y)-16.97%
ROE(3y)11.93%
ROE(5y)-401.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.04
Quick Ratio 7.04
Altman-Z -6.72
F-Score6
WACC9.23%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%368.94%
EPS Next Y67.52%
EPS Next 2Y-58.21%
EPS Next 3Y-18.91%
EPS Next 5Y16.98%
Revenue 1Y (TTM)449.95%
Revenue growth 3Y59.36%
Revenue growth 5YN/A
Sales Q2Q%1808.5%
Revenue Next Year660.43%
Revenue Next 2Y-38.5%
Revenue Next 3Y21.54%
Revenue Next 5Y31.87%
EBIT growth 1Y56.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y78%
OCF growth 3YN/A
OCF growth 5YN/A

SCYNEXIS INC / SCYX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for SCYNEXIS INC?

ChartMill assigns a fundamental rating of 4 / 10 to SCYX.


What is the valuation status for SCYX stock?

ChartMill assigns a valuation rating of 0 / 10 to SCYNEXIS INC (SCYX). This can be considered as Overvalued.


What is the profitability of SCYX stock?

SCYNEXIS INC (SCYX) has a profitability rating of 1 / 10.